Cambridge, UK. 22 October 2020. Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced that STC-15, its first-in-class drug candidate targeting […]